151 related articles for article (PubMed ID: 2286711)
1. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Simpson GM; Yadalam KG; Levinson DF; Stephanos MJ; Lo ES; Cooper TB
J Clin Psychopharmacol; 1990 Dec; 10(6):417-21. PubMed ID: 2286711
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of the depot antipsychotics.
Jann MW; Ereshefsky L; Saklad SR
Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
[TBL] [Abstract][Full Text] [Related]
4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
6. Lowest effective dose of depot neuroleptics.
Hoencamp E; Haffmans PJ; Jansen GS
Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
[No Abstract] [Full Text] [Related]
7. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
8. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
9. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
Siris SG; Adan F; Lee A; Cooper TB; Mandeli J; Casey E
J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
[TBL] [Abstract][Full Text] [Related]
11. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
Soni SD; Wiles D; Schiff AA; Bamrah JS
Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
15. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Wistedt B
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
[TBL] [Abstract][Full Text] [Related]
16. Fluphenazine decanoate: a clinical problem?
Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
[TBL] [Abstract][Full Text] [Related]
17. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
Glazer WM; Friedhoff LT; Marder SR; Brown WA
Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
[TBL] [Abstract][Full Text] [Related]
18. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
20. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
